Threat of SREs From Bone Metastases Increases As New Treatments in Breast Cancer Extend Survival
ZOMETA - Zoledronic AcidZOMETA - Zoledronic Acid Novartis Oncology
HomeZOMETA - International SiteZOMETA - US ResidentsZOMETA - Country Sites
ZOMETA - English ZOMETA - Deutsch ZOMETA - Espanol ZOMETA - Francais ZOMETA - Italiano
ZOMETA-Videos
Blue Arrow View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

 
ZOMETA European Summary of Product Characteristics
Blue Arrow For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics
 
About ZOMETA: defend against SREs across a broad range of tumour types

Page  1 2


As new treatments extend survival, the threat of SREs increases

  • The median survival of patients treated with paclitaxel + bevacizumab is more than 2 years—but half of all patients with untreated bone metastases from breast cancer will experience an SRE within 1 year2,4



Median time to first SRE vs median survival in breast cancer2,4

*Median time to first SRE in untreated patients in a clinical trial, excluding
hypercalcemia of malignancy. Median time to first SRE not reached in
patients treated with ZOMETA.
Median survival of patients treated with paclitaxel + bevacizumab.


Page  1 2